Stockscreener 앱 받기
1.10
2.80%
0.03
전일 마감가:
$1.07
열려 있는:
$1.08
하루 거래량:
1.01M
Relative Volume:
0.49
시가총액:
$178.68M
수익:
$400.57M
순이익/손실:
$9.21M
주가수익비율:
27.50
EPS:
0.04
순현금흐름:
$146.36M
1주 성능:
+0.92%
1개월 성능:
+43.32%
6개월 성능:
-42.11%
1년 성능:
-76.94%
1일 변동 폭
$1.04
$1.115
1주일 범위
$1.015
$1.15
52주 변동 폭
$0.5271
$5.205
아이언우드 제약 Stock (IRWD) Company Profile
명칭
Ironwood Pharmaceuticals Inc
전화
617-621-7722
주소
100 SUMMER STREET, SUITE 2300, BOSTON, MA
IRWD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
1.10 | 183.55M | 400.57M | 9.21M | 146.36M | 0.04 |
|
ZTS
Zoetis Inc
|
156.76 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.48 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.91 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.61 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
306.48 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
아이언우드 제약 Stock (IRWD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-04-15 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-04-14 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-09-09 | 개시 | Leerink Partners | Market Perform |
| 2024-08-08 | 다운그레이드 | CapitalOne | Overweight → Equal Weight |
| 2024-01-17 | 개시 | Craig Hallum | Buy |
| 2023-12-14 | 개시 | Wells Fargo | Overweight |
| 2023-11-09 | 개시 | Jefferies | Buy |
| 2023-09-28 | 개시 | JMP Securities | Mkt Outperform |
| 2022-09-02 | 개시 | CapitalOne | Overweight |
| 2022-04-22 | 개시 | Piper Sandler | Overweight |
| 2020-09-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-06-17 | 개시 | Northland Capital | Outperform |
| 2019-07-10 | 재개 | Credit Suisse | Neutral |
| 2019-03-27 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2019-02-25 | 업그레이드 | H.C. Wainwright | Sell → Neutral |
| 2019-01-24 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2018-11-07 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2018-11-07 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-07-23 | 개시 | H.C. Wainwright | Sell |
| 2018-05-09 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2018-01-05 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
| 2017-12-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2017-07-21 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2017-05-03 | 개시 | Wells Fargo | Outperform |
| 2017-04-07 | 재확인 | Mizuho | Buy |
| 2017-02-22 | 재확인 | Barclays | Equal Weight |
| 2016-11-04 | 재확인 | Mizuho | Buy |
| 2016-10-24 | 재확인 | Wedbush | Neutral |
| 2016-10-10 | 재확인 | Mizuho | Buy |
| 2016-09-27 | 재확인 | WallachBeth | Hold |
모두보기
아이언우드 제약 주식(IRWD)의 최신 뉴스
IRWD Stock Rises as Q2 Earnings & Revenues Trump Estimates - MSN
Sectors Driving Future Growth for Ironwood Pharmaceuticals Inc. StockTrade Volume Report & Real-Time Sentiment Analysis - Newser
Historical volatility pattern of Ironwood Pharmaceuticals Inc. visualizedJuly 2025 Opening Moves & Short-Term High Return Ideas - Newser
Measuring Ironwood Pharmaceuticals Inc.’s beta against major indicesMarket Rally & Entry Point Confirmation Alerts - Newser
Ironwood Pharmaceuticals Inc. Earnings Report Breakdown: What Investors Should KnowWeekly Stock Recap & Daily Oversold Bounce Ideas - Newser
Keep An Eye On Ironwood Pharmaceuticals As Insider Stock Selling Hits US$515k - simplywall.st
Will Ironwood Pharmaceuticals Inc. benefit from rate cuts2025 Top Gainers & Stepwise Entry and Exit Trade Signals - classian.co.kr
Volume spikes in Ironwood Pharmaceuticals Inc. stock – what they meanWeekly Market Report & AI Forecasted Entry/Exit Points - Newser
How to build a custom watchlist for Ironwood Pharmaceuticals Inc.Trade Risk Summary & Safe Entry Zone Identification - Newser
Risk adjusted return profile for Ironwood Pharmaceuticals Inc. analyzed2025 Investor Takeaways & AI Enhanced Trading Signals - Newser
Using fundamentals and technicals on Ironwood Pharmaceuticals Inc.Portfolio Return Summary & Weekly High Return Stock Opportunities - Newser
What to do if you’re stuck in Ironwood Pharmaceuticals Inc.Analyst Downgrade & Entry and Exit Point Strategies - Newser
Multi factor analysis applied to Ironwood Pharmaceuticals Inc.2025 Earnings Surprises & Stepwise Trade Signal Implementation - Newser
Published on: 2025-08-15 04:45:17 - Newser
Can Ironwood Pharmaceuticals Inc. be recession proofJuly 2025 Catalysts & Safe Entry Momentum Tips - classian.co.kr
Ironwood Pharmaceuticals Inc. Uptrend in Early Stages Indicators Say YesJuly 2025 Summary & AI Enhanced Trading Signals - newsyoung.net
Published on: 2025-08-14 14:41:22 - beatles.ru
Can Ironwood Pharmaceuticals Inc. expand its profit margins2025 Performance Recap & Verified Entry Point Detection - 선데이타임즈
Analysts’ Opinions Are Mixed on These Healthcare Stocks: 89bio (ETNB), Relay Therapeutics (RLAY) and Ironwood Pharma (IRWD) - The Globe and Mail
Short Bowel Syndrome Market to Experience Notable Growth - openPR.com
Short Bowel Syndrome Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts | Zealand Pharma, Ironwood Pharma, Hanmi Pharma, Shire, AbbVie, Hanmi Pharma - Barchart.com
How high can Ironwood Pharmaceuticals Inc. stock goSmart Entry Signals for Active Traders - Newser
Ironwood Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Ironwood: Q2 Earnings Snapshot - Connecticut Post
Ironwood Pharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Ironwood (IRWD) Q2 EPS Jumps 600% - AOL.com
Ironwood Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Ironwood Pharmaceuticals (IRWD.O) Surges 15.5% on Strong KDJ Signal Amid Mixed Peer Performance - AInvest
Ironwood Pharmaceuticals (IRWD) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance
Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance - BioSpace
Ironwood Pharmaceuticals Q2 2025 Earnings: EPS of $0.15 and Reve - GuruFocus
Ironwood Pharmaceuticals Tops Expectations With Strong Q2 Results - Finimize
Ironwood Pharmaceuticals (IRWD) Projected to Post Quarterly Earnings on Thursday - Defense World
Endometriosis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine Biosciences - The Globe and Mail
Ironwood Pharmaceuticals Inc expected to post earnings of 4 cents a shareEarnings Preview - TradingView
Custom Dashboard Highlights Ironwood Pharmaceuticals Inc. Price MomentumFundamental Growth Stock Analysis Shows Strength - beatles.ru
Published on: 2025-08-04 00:15:09 - Jammu Links News
What drives Ironwood Pharmaceuticals Inc. stock priceExpert guidance for superior capital growth - Jammu Links News
Is Ironwood Pharmaceuticals Inc. stock overvalued or undervaluedAchieve rapid portfolio growth with expert guidance - Jammu Links News
Is it the right time to buy Ironwood Pharmaceuticals Inc. stockOutstanding risk-reward balance - Jammu Links News
Is Ironwood Pharmaceuticals Inc. a growth stock or a value stockDiscover stocks with strong growth potential - Jammu Links News
What are the technical indicators suggesting about Ironwood Pharmaceuticals Inc.Build a winning investment strategy - Jammu Links News
What are the latest earnings results for Ironwood Pharmaceuticals Inc.Unprecedented growth rates - Jammu Links News
What catalysts could drive Ironwood Pharmaceuticals Inc. stock higher in 2025Achieve breakthrough financial growth - Jammu Links News
How strong is Ironwood Pharmaceuticals Inc. company’s balance sheetDynamic portfolio growth - Jammu Links News
What makes Ironwood Pharmaceuticals Inc. stock price move sharplyExceptional financial outcomes - Jammu Links News
What Fibonacci levels say about Ironwood Pharmaceuticals Inc. reboundAutomated AI Forecast with Trading Alerts - Newser
아이언우드 제약 (IRWD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
아이언우드 제약 주식 (IRWD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| John Minardo | Chief Legal Officer |
Aug 11 '25 |
Sale |
0.84 |
7,754 |
6,513 |
400,378 |
| Martini Gregory S. | Chief Financial Officer |
Aug 11 '25 |
Sale |
0.84 |
1,265 |
1,063 |
182,545 |
| Silver Ronald | Principal Accounting Officer |
Aug 11 '25 |
Sale |
0.84 |
2,846 |
2,391 |
276,809 |
0.42%
0.34%
자본화:
|
볼륨(24시간):